Skip to content

20-046 - Investigating Study Medication Versus Placebo in Participants With High-Risk Breast Cancer

Status: open

A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7FL)

Treatment for Breast Cancer

Contact Us


A randomized multi-arm study evaluating the safety and efficacy of nivolumab versus placebo in combination with paclitaxel in participants with ER+/HER2- breast cancer


This trial is sponsored by Bristol-Myers Squibb.

Providers Associated With This Trial

Sub Investigators

    This link will open in a new tab or window.